Compare Becton Dickinson and Co (BDX) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs MakeMyTrip Ltd — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $49.41B), while MakeMyTrip Ltd trades at $60.56 (market cap $5.78B). The key difference: Becton Dickinson and Co is far larger — about 8.5× MakeMyTrip Ltd's market cap, and Becton Dickinson and Co pays a 2.32% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| BDX | MMYT | |
|---|---|---|
Market Cap | $49.41B | $5.78B |
Sector | Health | Technology |
52-Week High | $185.39 | $103.21 |
52-Week Low | $138.62 | $36.30 |
Enterprise Value | $65.51B | $6.44B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $183.71, up 2.27% today, near its consensus price target of $183.00. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $21.84 billion in 2025, with consistent earnings beats in recent quarters, including Q3 2026 EPS of $3.23 beating estimates. The company maintains a dividend of $1.05 per share and recently raised full-year guidance, reflecting operational strength amid tariff pressures.
Outlook remains positive with raised profit guidance and segment growth, but risks include margin pressure from tariffs and a product recall. Analyst sentiment is mixed with 47% buy ratings, suggesting cautious optimism. The stock offers stability as a Dividend Aristocrat with growth catalysts from medical technology advancements, though investors should monitor margin trends and competitive dynamics.
MakeMyTrip (MMYT) trades at $60.31, down 0.99% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth to $978M in 2025 and consistent earnings beats, though Q2 2026 missed expectations. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target. Recent news highlights travel industry momentum despite temporary air-ticketing softness.
Investment outlook appears favorable with strong fundamentals and bullish analyst consensus, though risks include rising debt levels and geopolitical travel disruptions. The stock's high P/E ratio of 267 requires sustained earnings growth to justify valuation. Recent institutional selling by Boston Common Asset Management warrants monitoring for broader sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
